Increased oxidative stress (36), chronic subclinical inflammation (37), reduced levels of adiponectin (38) and altered production of coagulant factors can be involved in the pathogenesis of atherosclerosis in patients with NAFLD. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.